LB-151

LB-151 is a small molecule inhibitor of protein phosphatase 2A (PP2A) developed by Lixte Biotechnology Holdings. It belongs to a class of phosphatase inhibitors designed to enhance the effectiveness of chemotherapy and radiation by interfering with DNA damage repair mechanisms and cell cycle checkpoints in cancer cells. LB-151 was utilized in foundational research at the H. Lee Moffitt Cancer Center and Research Institute, which led to the development of patents for oncology diagnostics and therapeutics, specifically targeting myelodysplastic syndrome (MDS). While Lixte's lead compound, LB-100, has advanced into clinical trials, LB-151 remains a key asset in the company's intellectual property portfolio for the treatment of hematologic malignancies and other solid tumors.